Advertisement
JOGC

Impact of a Clinical Intervention to Decrease Opioid Prescribing in a Postcesarean Delivery

Published:November 27, 2021DOI:https://doi.org/10.1016/j.jogc.2021.11.009

      Abstract

      A quality assurance study was completed following the implementation of a standardized opioid prescribing and education protocol post cesarean delivery. The primary goal was to determine the need for a policy on postpartum opioid prescribing practices and whether the protocol worked. There was a decrease in the number of tablets provided post intervention and no statistically significant maternal or neonatal readmissions for suspected opioid toxicity or pain control. Combination prescribing of Tylenol 3 and/or tramadol and another opioid occurred in both groups. Our results show a need for concise guidelines regarding opioid prescribing following cesarean delivery.

      Résumé

      Une étude sur l’assurance de la qualité a été réalisée après la mise en œuvre d’un protocole normalisé de prescription et d’information concernant les opioïdes après une césarienne. L’objectif principal était d’étudier la nécessité d’une politique sur les pratiques de prescription d’opioïdes post-partum et de déterminer si le protocole était efficace. Il y a eu une diminution du nombre de comprimés fournis après l’intervention et aucune différence statistiquement significative n’a été observée concernant les réadmissions maternelles ou néonatales relativement à une intoxication soupçonnée aux opioïdes ou au traitement de la douleur. Des ordonnances combinées avec Tylenol no 3 et/ou tramadol et un autre opioïde ont été prescrites dans les deux groupes. Nos résultats montrent un besoin de lignes directrices concises concernant la prescription d’opioïdes après une césarienne.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Osmondson S.S.
        • Wiese A.D.
        • Min J.Y.
        • et al.
        Delivery type, opioid prescribing, and the risk of persistent opioid use after delivery.
        Am J Obstet Gynecol. 2019; 220: 405-407
        • Peahl A.F.
        • Dalton V.K.
        • Montgomery J.R.
        • et al.
        Rates of new persistent opioid use after vaginal or caesarean birth among US women.
        JAMA Network Open. 2019; 2
        • Ilett K.F.
        • Paech M.J.
        • Page-Sharp M.
        • et al.
        Use of a sparse sampling study design to assess transfer of tramadol and its O – desmethyl metabolite into transitional breast milk.
        Br J Clin Pharmacol. 2008; 65: 661-666
        • Center for Drug Evaluation and Research
        FDA drug safety communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women.
        (Available at:) (Accessed December 22, 2021)
        • Ho A.M.
        • Phelan R.
        • Mizubuti G.B.
        • et al.
        Bias in before–after studies.
        Anesth Analg. 2018; 126: 1755-1762
        • Alberta Health Services
        The Alberta pain strategy: achieving excellence in pain management.
        (Available at:) (Accessed December 22, 2021)
        • Prabhu M.
        • Dubois H.
        • James K.
        • et al.
        Implementation of a quality improvement initiative to decrease opioid prescribing after cesarean delivery.
        Obstet Gynecol. 2018; 132: 631